Depypere L, Moons J, Lerut T, De Hertogh G, Peters C, Sagaert X, Coosemans W, Van Veer H, Nafteux P
Department of Thoracic Surgery.
Department of Pathology, University Hospital Leuven, Leuven, Belgium.
Dis Esophagus. 2018 Feb 1;31(2). doi: 10.1093/dote/dox117.
The accepted importance of a positive circumferential resection margin (CRM) (defined as R1 in the TNM classification) is based on histopathology of the resection specimen obtained after primary surgery in esophageal cancer patients. The aim of this study is to look for the prognostic value of CRM after neoadjuvant chemoradiotherapy and to compare the clinical significance of a histologically CRM < 1 mm from the cut margin (Royal College of Pathologists definition of R1) to a positive cut margin (College of American Pathologists definition of R1) and to ≥1 mm margin (R0) resections in patients with ypT3-esophageal tumors after neoadjuvant chemoradiotherapy. Between 2000 and 2014, 458 patients who received esophagectomy after neoadjuvant chemoradiation therapy were selected. Overall (OS) and disease-free survival (DFS) were calculated by means of Kaplan-Meier curves and compared by Cox regression analysis. There were 163 (35.9%) patients who had a ypT3 tumor; in 118 (72.4%) resection was complete (R0). In 37 (22.7%) patients a CRM < 1 mm was found and 8 (4.9%) had a circumferential R1-resection. CRM involvement was inversely correlated with tumor regression grading, lymph node capsular involvement, and number of positive lymph nodes. On univariate analysis, no statistically significant difference was found between R0-resection and CRM < 1 mm (P = 0.103) for OS, but DFS showed a significant difference (P = 0.025). Circumferential R1-resections showed a significant difference compared to R0-resections for OS and DFS (both P = 0.002). In multivariate analysis, extracapsular lymph node involvement and circumferential R1-resection were withheld as independent prognosticators for OS, whereas extracapsular lymph node involvement, absence of regression on the primary tumor and circumferential R1-resection were withheld for DFS. After correcting for different variables in the multivariate model, CRM < 1 mm showed no statistical difference compared to R0-resections neither for OS nor for DFS. After neoadjuvant chemoradiotherapy, CRM is correlated with biological behavior of the tumor and with therapy response. Furthermore it is an independent prognosticator for OS and DFS. However CRM < 1 mm itself is no independent prognosticator for OS nor DFS survival in multivariable analysis. These results suggest that the definition of R1-resection should be limited to true invasion of the section plane.
环周切缘阳性(CRM,在TNM分类中定义为R1)已被认可的重要性基于食管癌患者初次手术后获得的切除标本的组织病理学检查。本研究的目的是探寻新辅助放化疗后CRM的预后价值,并比较组织学上CRM距切缘<1mm(皇家病理学家学会对R1的定义)与切缘阳性(美国病理学家学会对R1的定义)以及新辅助放化疗后ypT3期食管肿瘤患者切缘≥1mm(R0)切除的临床意义。在2000年至2014年期间,选取了458例接受新辅助放化疗后行食管切除术的患者。通过Kaplan-Meier曲线计算总生存期(OS)和无病生存期(DFS),并通过Cox回归分析进行比较。有163例(35.9%)患者为ypT3期肿瘤;其中118例(72.4%)切除完整(R0)。在37例(22.7%)患者中发现CRM<1mm,8例(4.9%)为环周R1切除。CRM受累与肿瘤退缩分级、淋巴结包膜受累及阳性淋巴结数量呈负相关。单因素分析显示,R0切除与CRM<1mm之间OS无统计学显著差异(P = 0.103),但DFS有显著差异(P = 0.025)。环周R1切除与R0切除相比,OS和DFS均有显著差异(均P = 0.002)。多因素分析中,淋巴结外膜受累和环周R1切除是OS的独立预后因素,而淋巴结外膜受累、原发肿瘤无退缩及环周R1切除是DFS的独立预后因素。在多变量模型中校正不同变量后,CRM<1mm与R0切除相比,OS和DFS均无统计学差异。新辅助放化疗后,CRM与肿瘤的生物学行为及治疗反应相关。此外,它是OS和DFS的独立预后因素。然而,在多变量分析中,CRM<1mm本身并非OS和DFS生存的独立预后因素。这些结果表明,R1切除的定义应限于切面的真正侵犯。